![]() | |
Clinical data | |
---|---|
Trade names | Naxcel |
AHFS/Drugs.com | International Drug Names |
ATCvet code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H17N5O7S3 |
Molar mass | 523.55 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987.[2] It is marketed by pharmaceutical company ZoetisasExcenel,[3] Naxcel, and Excede and is also the active ingredient in that company's Spectramast LC (lactating cow formulation) and Spectramast DC (dry cow formulation) product.[citation needed]
It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against both Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported.[4]
The metabolite desfuroylceftiofur also has antibiotic activity.[5] The two compounds are measured together to measure for antibiotic activity in milk (alongside other antibiotics).[6]
![]() | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |